BIONET Therapeutics Corp. (TPEX:7808)
Taiwan · Delayed Price · Currency is TWD 34.95
-0.05 (-0.14%)
At close: Sep 17, 2026
BIONET Therapeutics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Net Income | -84.09 | -97.43 | -86.26 | -37.34 | -12.52 |
Depreciation & Amortization | 20.68 | 11.77 | 3.24 | 0.58 | - |
Loss (Gain) From Sale of Investments | -0.03 | -0.14 | -0.71 | -0.03 | - |
Stock-Based Compensation | 18.92 | 18.69 | 3.71 | 0.16 | - |
Provision & Write-off of Bad Debts | 1.02 | 0.01 | 0.01 | - | - |
Other Operating Activities | -1.1 | -1.64 | -4.99 | -1.6 | - |
Change in Accounts Receivable | -15.24 | -13.24 | -10.27 | -1.17 | - |
Change in Inventory | -9.11 | -0.56 | -29.15 | -0.37 | - |
Change in Accounts Payable | 3.07 | -9.17 | 11.61 | 4.55 | 1.17 |
Change in Unearned Revenue | 16.66 | 6.98 | 1.71 | 2.61 | - |
Change in Other Net Operating Assets | 2.83 | 13.84 | 2.69 | -1.55 | 7.87 |
Operating Cash Flow | -38.46 | -57.48 | -124.39 | -34.16 | -3.47 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Capital Expenditures | -52.33 | -81.19 | -46.56 | -12.1 | - |
Sale (Purchase) of Intangibles | -4.94 | -2 | -0.46 | - | - |
Investment in Securities | 109.45 | 219 | -707.09 | -478.99 | - |
Other Investing Activities | 0.05 | -0.06 | -0.68 | -0.01 | - |
Investing Cash Flow | 52.23 | 135.75 | -754.8 | -491.09 | - |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Long-Term Debt Repaid | - | -0.71 | - | - | - |
Lease Payments | -2.25 | -0.71 | - | - | - |
Net Debt Issued (Repaid) | -2.25 | -0.71 | - | - | - |
Issuance of Common Stock | - | - | 855.85 | 516.57 | 96 |
Financing Cash Flow | -2.25 | -0.71 | 855.85 | 516.57 | 96 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Net Cash Flow | 11.52 | 77.56 | -23.33 | -8.67 | 92.53 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -90.79 | -138.68 | -170.95 | -46.26 | -3.47 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -46.17% | -89.77% | -210.22% | -861.52% | - |
Free Cash Flow Per Share | -1.30 | -1.98 | -2.98 | -3.06 | -3.17 |
Levered Free Cash Flow | -86.53 | -140.06 | -116.82 | -33.11 | - |
Unlevered Free Cash Flow | -86.3 | -140.01 | -116.82 | -33.11 | - |
Free Cash Flow After Leases | -93.03 | -139.39 | -170.95 | -46.26 | -3.47 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash Interest Paid | 0.37 | 0.08 | - | - | - |
Cash Income Tax Paid | 1.03 | 1.76 | 0.71 | 0.02 | - |
Change in Working Capital | 6.14 | 11.26 | -39.4 | 4.07 | 9.04 |